Results of a retrospective claims database analysis suggest that adherence to scheduled intrathecal nusinersen injections may lead to improvements in comorbidities, health care utilization, and costs ...

A novel indwelling subcutaneous intrathecal catheter circumvented the complex spine anatomy of patients with spinal muscular atrophy (SMA), a challenge when giving nusinersen via intrathecal injection ...

Nusinersen injection is injected intrathecally (into the backbone) over 1-3 minutes so that it reaches the cerebrospinal fluid (CSF), the fluid that bathes the brain and the spinal cord. Dosage & When ...

The US Food and Drug Administration (FDA) has approved nusinersen (Spinraza, Biogen and Ionis Pharmaceuticals), the first drug approved to treat children and adults with spinal muscular atrophy (SMA), ...

Recent approvals of antisense therapies for spinal muscular atrophy and Duchenne muscular dystrophy have bolstered hopes for targeting RNA to treat a plethora of neurodegenerative brain disorders. At ...

Treatment with SPINRAZA™ resulted in survival of 100 percent of infants and none requiring permanent ventilation Recently published outcomes include motor milestones achieved in 100 percent of infants ...

Nusinersen, a drug that has recently been approved for the treatment of spinal muscle atrophy (SMA) improves muscle function and prolongs life in SMA patients. Nusinersen is a targeted therapy ...

LOS ANGELES — Longer-term use of the antisense oligonucleotide nusinersen (Spinraza, Biogen) is both safe and effective in children with infantile-onset spinal muscular atrophy (SMA), new research ...

Treatment with SPINRAZA™ resulted in survival of 100 percent of infants and none requiring permanent ventilation Recently published outcomes include motor milestones achieved in 100 percent of infants ...